The role of coenzyme Q10 in breast cancer

Zayneb A. Mohammed; Haydar F. Al-Tukmagi; Hassan M. Abbas

The role of coenzyme Q10 in breast cancer

Zayneb A. Mohammed, Haydar F. Al-Tukmagi, Hassan M. Abbas

Abstract

Oxidative stress plays a crucial role in pathogenesis as well as progression of all cancers including breast cancer. The aim of the present study was to explore the possible protective effects of coenzyme Q10, an antioxidant agent, on Doxorubicin induced cardiotoxicity in breast cancer patients, we also investigated the role of coenzyme Q10 on oxidative stress. Sixty-four women having histologically confirmed breast cancer participated in this study. The patients divided into two groups. Group (A) who treated with coenzyme Q10 supplement in addition to chemotherapy adriamycin plus cyclophosphamide (AC). Group (B) treated with chemotherapy only. In this study, serum coenzyme Q10, malondialdehyde (MDA), total antioxidant status (TAS), complete blood count (CBC), serum ALT, AST, creatine kinase (CK), renal functions (serum creatinine and urea), creatine phosphokinase (CPK), high sensitivity C-Reactive protein (hs-CRP) levels were determined. Ejection Fraction (EF) was determined by echocardiography for all participants at baseline as well as post treatment. Statistical analysis was performed using SPSS, version 23, USA for WINDOWS, results are defined as mean ± standard deviation SD. Serum coenzyme Q10, total antioxidant status (TAS) were low at baseline in both groups, serum malondialdehyde (MDA), high sensitivity C-reactive protein (hs-CRP) levels had decreased significantly after supplementation with coenzyme Q10. The reduction in EF was more pronounced in group
B at the end of the work. The present study demonstrated that women with breast cancer have a low level of coenzyme Q10 as compared to those of healthy women. It also emphasizes the growing concern that oxidative damage may occur in those patients that exhaust the antioxidant defense of the body leading to a low levels of Coenzyme Q10 and TAS and increasing in inflammatory markers as well as oxidative stress markers which lead to cardiotoxicity. Administration of antioxidant supplements such as a coenzyme Q10 is necessary in women with breast cancer postoperative with adjuvant chemotherapy to minimizes its cardiotoxicity.

Keywords

breast cancer, coenzyme Q10, oxidative stress

Full Text:

References

DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA a Cancer J Clin. 2014;64:52–62.

Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast Cancer: Epidemiology and Etiology. Cell Biochem Biophys. 2015;72: 333–338.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.

Malhotra GK, Zhao X, Band H, Band V. Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther. 2010;10:955–960.

Beral V, Reeves G, Bull D, Green J. Million Women Study Collaborators. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst. 2011;103:296–305.

Thomas S. Cancer As a Metabolic Disease: On The Origin, Management, and Prevention of Cancer. John Wiley & Sons, 2012.

Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18:1639–1642.

Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy: from the cardiotoxic mechanisms to management. Progress in cardiovascular diseases. 2007;49(5):330–52.

Gönenç A, Ozkan Y, Torun M, Sim?ek B. Plasma malondialdehyde (MDA) levels in breast and lung cancer patients. J Clin Pharm Ther. 2001;26:141–144.

Czarnecka AM, Krawczyk T, Zdro?ny M, Lubi?ski J, Arnold RS, Kukwa W, et al. Mitochondrial NADH-dehydrogenase subunit 3 (ND3) polymorphism (A10398G) and sporadic breast

cancer in Poland. Breast cancer research and treatment. 2010;121(2):511–8.

Halliwell B. Oxidative stress and cancer: have we moved forward? Biochem J. 2007;401:1–11.

Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem. 2004;266:37–56.

Maria Zowczak-Drabarczyk M, Murawa D, Kaczmarek L, Po?om K, Litwiniuk M. Total antioxidant status in plasma of breast cancer patients in relation to ER? expression. Contemp Oncol (Pozn). 2013;17:499–503.

Gönenç A, Erten D, Aslan S, Akinci M, Sim?ek B, Torun M. Lipid peroxidation and antioxidant status in blood and tissue of malignant breast tumor and benign breast disease. Cell Biol Int. 2006;30:376–380.

Lee BJ, Huang YC, Chen SJ, Lin PT. Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease. Nutrition. 2012;28:767–772.

Chai W, Cooney RV, Franke AA, Shvetsov YB, Caberto CP, Wilkens LR, et al. Plasma coenzyme Q10 levels and postmenopausal breast cancer risk: the multiethnic cohort study. Cancer Epidemiology Biomarkers & Prevention. 2010;19(9):2351–6.

Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ, Pella D, et al. Q-SYMBIO Study Investigators. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2012:4;641–649.

Niklowitz P, Onur S, Fischer A, Laudes M, Palussen M, Menke F, et al. Coenzyme Q10 serum concentration and redox status in European adults: influence of age, sex, and lipoprotein concentration. J Clin Biochem Nutr. 2016;58:240–245.

Anna G, Toru T, Singh RB, Meester D, Wilson F, Douglas W, et al. New roles of coenzyme Q10 in cardiovascular diseases, discovered by a single group. World Heart J. 2013;5:159–171.

Guo YZ, Pan L, Du CJ, Ren DQ, Xie XM. Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pac J Cancer Prev. 2013;14:243–248.

Portakal O, Ozkaya O, Erden Inal M, Bozan B, Ko?an M, Sayek I. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clinical Biochem. 2000;33:279–284.

Kasapovi? J, Peji? S, Todorovi? A, Stojiljkovi? V, Pajovi? SB. Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages. Cell Biochem Funct. 2008;26:723–730.

Shilpa HD, Anita R Bijoor. Malondialdehyde as a marker of lipid peroxidation in acute myocardial infarction patients. MRIMS journal of Health Sciences. 2013;1:20–22.

Del Pozo-Cruz J, Rodríguez-Bies E, Navas-Enamorado I, Del Pozo- Cruz B, Navas P, López-Lluch G. Relationship between functional capacity and body mass index with plasma coenzyme Q10 and oxidative damage in community-dwelling elderly people. Exp Gerontol. 2014;52:46–54.

Basu S, Harris H, Larsson A, Vasson MP, Wolk A. Is there any role for serum cathepsin S and CRP levels on prognostic information in breast cancer? The Swedish mammography cohort. Antioxid Redox Signal. 2015;23:1298–302.

Sara JD, Zhang M, Lennon R, Herrmann J, Lerman L, Lerman A. High sensitivity C-reactive protein is an independent marker of coronary endothelial dysfunction in patients with non obstructive coronary artery disease. J Am Coll Cardiol. 2016;67:360–360.

Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast Cancer: epidemiology and etiology. Cell Biochem Biophys. 2015;72:333–338.

Refbacks

There are currently no refbacks.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Journal of Pharmaceutical and Biomedical Sciences